Journal of Biomedical and Pharmaceutical Research
Available Online at www.jbpr.in
CODEN: - JBPRAU (Source: - American Chemical Society)
NLM (National Library of Medicine): ID: (101671502)
Index Copernicus Value 2023: 85.868
Volume 14, Issue 2; 2025, 19-27

ISSN (Online): 2279-0594
ISSN (Print): 2589-8752

Review Article

Current Perspectives on Cystic Fibrosis: Pathogenesis, Management, and Therapeutic Advances

G Sathwika[1*], S Sri Divya[2], G Vanaja[3], K Sai Dharani[4]

[1, 2, 3, 4]**B.Pharmacy 4th Year Students, Anurag Pharmacy College, Kodad, Telangana**

Article Info: Received: 11-01-2025 / Revised: 19-02-2025 / Accepted: 09-03-2025
Corresponding Author: G Sathwika
DOI: https://doi.org/10.32553/jbpr.v14i2.1255
Conflict of interest statement: No conflict of interest

Abstract:

Introduction: Cystic fibrosis (CF) is a genetic disorder caused by mutations in the CFTR gene, leading to thick mucus buildup that primarily affects the respiratory and digestive systems. It results in chronic lung infections, malabsorption, and reduced life expectancy.

Objectives: This review aims to explore CF's pathophysiology, genetic basis, clinical manifestations, diagnostic advancements, and emerging treatment strategies.

Methods: A systematic literature review was conducted using peer-reviewed sources from PubMed, NIH, and other medical databases, focusing on CFTR mutations, disease progression, and treatment innovations, including CFTR modulators and gene therapy.

Results & Discussion: Advancements in CF diagnosis, such as newborn screening and genetic testing, enable early detection. Treatments include CFTR modulators, antibiotics, mucolytics, bronchodilators, and enzyme replacement therapy. Non-pharmacological approaches, such as airway clearance techniques and lung transplantation, further improve outcomes. Research in gene editing and personalized medicine offers hope for future breakthroughs.

Conclusion: While CF remains a life-threatening condition, advancements in treatment and early diagnosis have significantly improved patient outcomes. Continued research in gene therapy and precision medicine holds promise for more effective and targeted therapies.

Keywords: Cystic Fibrosis, CFTR, Genetic Disorder, Lung Disease

Introduction

Definition

Cystic fibrosis is a genetic condition that changes a protein in the body. The faulty protein affects the body's cells, tissues, and the glands that make mucus and sweat. The medical abbreviation of cystic fibrosis is CF.

Normal mucus is slippery and protects the airways, digestive tract, and other organs and tissues. Cystic fibrosis causes mucus to become thick and sticky. As mucus builds up, it can cause blockages, damage, or infections in affected organs [1].

Prevalence

The life-threatening recessive disorder CF causes mucus and sweat cells to develop complications that chiefly attack the lungs until they ultimately kill roughly 90% of individuals. The Cystic fibrosis trans-membrane conductance regulator (CFTR) gene mutation alters the protein functional as a regulated chloride channel that manages various chloride and sodium channels at the cell surface epithelium. The total worldwide CF cases level at 70,000 and the disease adds around 1000 new cases per year. White individuals with north European heritage have one CF birth in 2000 to 3000 newborns but Asian-Americans experience this condition at 1:30,000 birth rates. Cystic fibrosis (CF) stands as the major genetic disorder among Caucasians affecting 1 of every 2,500 to 3,500 live births [2].

Historical Background

Dr. Dorothy Andersen identified cystic fibrosis as "cystic fibrosis of the pancreas" during her initial diagnosis in 1938. During this same period medical experts described Cystic Fibrosis by two names which were based on both disease characteristics. Dr. Paul di Sant'Agnese discovered during 1948 that infected infants had unusually high salt content in their sweat. Scientific discoveries of the CFTR gene in combination with protein defect identification enabled researchers to develop therapeutic advances that resulted in enhanced survival statistics [3].

CFTR Mutation

Cystic fibrosis emerges from gene mutations in CFTR that produce instructions for creating the CFTR protein. People with two mutation-bearing CFTR genes end up creating a faulty protein that causes cell salt regulation failure. The abnormalities produce thickening mucus which obstructs airways and interrupts breathing patterns while causing damage throughout the digestive organ [4].

Inheritance

Every person inherits two CFTR genes: one gene from each parent. A child inherits cystic fibrosis upon receiving CFTR gene mutations from both parents simultaneously. A person will carry the cystic fibrosis gene if they inherit a mutated CFTR gene from one parent while inheriting a normal CFTR gene from the other parent. Mutated CFTR gene inheritance possibilities from cystic fibrosis carriers will transfer to their offspring. Most carriers stay healthy although they could experience slight cystic fibrosis symptoms [4].

If both parents have a normal CFTR gene and a mutated CFTR gene, each of their children has a:

- 25% (1 in 4) chance of inheriting two normal CFTR genes
- 50% (1 in 2) chance of being a cystic fibrosis carrier, because they inherit one normal gene and one mutated gene
- 25% (1 in 4) chance of inheriting two genes with mutations and having cystic fibrosis [4]

Methodology

This review on cystic fibrosis (CF) is based on an extensive analysis of peer-reviewed literature, clinical studies, and authoritative medical sources. Data were collected from scientific databases such as PubMed, NIH, and medical journals, focusing on CF pathophysiology, genetic mutations, clinical manifestations, diagnostic methods, and treatment advancements. Studies were selected based on relevance, credibility, and recent developments in CF research. Key areas explored include CFTR mutations, disease progression, emerging gene-based therapies, and current management strategies. The findings were synthesized to provide a comprehensive understanding of CF, its complications, and potential future treatment directions.

Discussion

Pathophysiology of Cystic Fibrosis

CFTR disease-causing mutations have been categorized into the following dysfunctional variants, classes I through V:

- Class I dysfunction arises from three types of mutations in the mRNA sequence that end the protein development prematurely. The total failure of CFTR protein expression occurs when translational failure takes effect. Among the multiple cystic fibrosis mutation types Class I mutations exist as the least common at 2% to 5% of all cases.

- An abnormal or dysfunctional posttranslational processing of CFTR proteins due to Class II dysfunction blocks normal intracellular protein transit. Existence of CFTR prevents its proper transportation to the cellular destination.
- The third level of dysfunction leads to reduced protein activity after intracellular signaling occurs. The membrane ends up containing a properly structured but inactive protein channel.
- A Class IV dysfunction induces the protein to correctly position within the cell surface but decreases the chloride ion flow rate during activation periods. Following stimulation, the channel activation duration becomes shorter than normal while chloride ion flow rate decreases from its standard levels.
- Class V dysfunction appears when cellular processes destroy CFTR channels quickly leading to reduced CFTR channels in the cellular membrane. The stability of both mRNA and mature CFTR protein comes under the jurisdiction of Class V dysfunction [5].

Clinical Manifestations

Systemic Pathophysiologic Manifestations of Cystic Fibrosis

The reduction of chloride secretion from mutations causes sodium reabsorption to increase inside cells. Elevated sodium reabsorption creates more water reabsorption that eventually produces thicker mucus secretions for epithelial surfaces and exocrine glands generate more viscous secretions. Segmental mucus thickening takes place in nearly every affected organ system leading to mucous blockages that result in multiple obstruction-related diseases. The sinuses together with lungs and pancreas and biliary and hepatic systems and intestines and sweet glands are the organs that experience the highest impact from this disease [5].

Pulmonary Disease

The main symptom of cystic fibrosis pulmonary disease consists of airway blockages caused by excessive mucus buildup. Pulmonary disease in cystic fibrosis starts after birth when infections set off inflammatory processes which eventually block bronchiole passageways thus resembling obstructive lung disease. The obstruction enables bacterial growth that creates bronchiectasis and results in thick and purulent sputum formation. Airway inflammation worsens because neutrophils produce interleukin-8 which causes more mucus production resulting in continued airway damage and increased infection risk. The deterioration from this process progressively restricts breathing pathways until it causes death by respiratory arrest which represents the main reason for mortality among CF patients [5].

Pancreatic and Hepatic Disorders

Pancreatic complications in cystic fibrosis (CF) develop because thickened secretions close down pancreatic ductules which blocks digestive enzymes from reaching the small intestine. Due to pancreatic ductule blockage sodium bicarbonate levels decrease which causes both pH reduction and enzyme impairment resulting in nutrient malabsorption especially fat-soluble vitamins A, D, E, and K. The affected person will exhibit symptoms such as greasy stools and abdominal pain with cramping as well as vitamin deficiencies. Medical professionals describe severe pancreatic autodigestion from trapped enzymes as a condition which triggers pancreatitis and may result in endocrine pancreatic failure that resembles type 1 diabetes. Thick mucus disrupts biliary and hepatic systems by blocking ducts thus causing obstructive cirrhosis together with posthepatic hyperbilirubinemia. A rise in portal vein pressure generates various complications that involve the development of esophageal varices and both splenomegaly and hypersplenism. The medical treatment of cystic fibrosis becomes more complicated because 15% of patients with this condition develop gallstones [5].

Sweat gland manifestations

The chloride flow operates in reverse direction in the sweat glands of cystic fibrosis when compared with other tissues expressing CFTR. Chloride ions usually enter cellular spaces to enable sodium and water molecules to return back to the body. The excessive sodium loss on skin surface becomes evident because of defective CFTR channels that block chloride reabsorption in CF patients thus causing their specific salty skin manifestation. The body can develop hyponatremic dehydration through fluid loss during both hot conditions and severe cases. CFTR engages with numerous cellular elements through PDZ-type receptors which connects the protein to other transporters and signaling proteins and ion channels. Every interaction between CFTR proteins plays an essential role in managing transepithelial ion transport which expands the scope of CFTR functions beyond its traditional ion channel characteristics [5].

Diagnosis of Cystic Fibrosis

- **Newborn screening**: The procedure of newborn screening became universal throughout all 50 U.S. states along with the District of Columbia during the previous ten years. The test reveals infants with excessive levels of immunoreactive trypsin (IRT) enzymes in their blood. The pancreas sustains injury to cause this development. Additionally the test requires retesting in case of abnormal results. The screening process in particular states includes examining samples for the well-known deltaF508 gene mutation. Following the initial assessment the infant must be sent for additional testing because numerous screening results turn out to be incorrect. Doctors must extract blood to verify if the infant carries two genes for CF or conduct the sweat test procedure. Newborn screening follows different procedures in each state and you should discuss with your healthcare provider the steps their state uses to handle a test result that is uncertain. Testing infants ahead of time detects disorders early before proper treatment becomes available [6].
- **Genetic testing**: Scientists have discovered over 2,000 separate forms of mutations that affect the CF gene. The deltaF508 mutation remains the most prevalent among the approximately 2,000 CF gene variations which tend to occur with lowfrequency in the population except for this specific case. DNA testing procedures provide exact details about gene mutations during most genomic analyses. Genetic testing plays an essential role in family planning for people seeking to have children because more than 10 million US residents possess CF genes. During pregnancies the likelihood of getting CF reaches 25% whenever both parents carry genes that cause the condition [6].
- **Sweat test**: The chloride measurement takes place after practitioners collect sweat from a small forearm area. The inability of CFTR to reabsorb sweat salts leads to higher sweat chloride measurement levels in children with CF.
- **Measuring nasal lining:** The procedure to measure nasal potential difference is officially known as NPD. An electrical test on nasal epithelium can serve as an additional diagnostic method. The measurement takes place after medical professionals apply different solutions to the nasal lining. The test results for CF patients differ remarkably from those of non-CF patients which helps medical professionals make a diagnosis [6].

Treatment for Cystic Fibrosis

Available treatments exist to help control symptoms while decreasing complications and enhancing disease management for cystic fibrosis patients. Doctor visits must remain a fundamental practice to track the disease because treatment plans should be customized for every patient. Different health professionals make up the management team for cystic fibrosis treatment but intensive care in hospital settings becomes necessary sometimes [7].

Pharmacological Treatment

1. **Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators**

These drugs target the defective CFTR protein, which causes the abnormal mucus production in CF. These medications help the CFTR protein work more effectively or restore its function [8].

- **Ivacaftor (Kalydeco)**: Helps to open the CFTR channels in the cell membrane, improving chloride transport.
- **Lumacaftor/Ivacaftor (Orkambi)**: A combination therapy where lumacaftor helps the CFTR protein fold properly, while ivacaftor helps it open correctly.
- **Tezacaftor/Ivacaftor (Symdeko)**: Similar to Orkambi, this combination therapy aims to improve CFTR protein function.
- **Elexacaftor/Tezacaftor/Ivacaftor (Trikafta)**: A highly effective triple combination therapy for patients with at least one F508del mutation, the most common CF mutation [8].

2. **Antibiotics**

CF patients are prone to lung infections, often caused by bacteria such as Pseudomonas aeruginosa. Antibiotics help treat and prevent these infections.

- **Inhaled antibiotics**: These are used to target lung infections directly in the airways, such as:
  - **Tobramycin**
  - **Aztreonam**
  - **Colistin**
- **Oral or intravenous antibiotics**: For more severe or systemic infections, antibiotics like cephalexin, ciprofloxacin, and meropenem may be used **[8].**

3. **Mucolytics**

Mucolytics help to thin the thick mucus in the lungs, making it easier to clear out and improving lung function.

- **Dornase alfa (Pulmozyme)**: A recombinant enzyme that breaks down the DNA in mucus, thinning it and improving its clearance.
- **Hypertonic saline (HyperSal)**: A salt solution inhaled to help loosen the mucus in the airways [9].

4. **Bronchodilators**

These medications help open the airways, making it easier to breathe by relaxing the muscles around the airways.

- **Albuterol (Ventolin)**: A short-acting bronchodilator used to relieve symptoms of airway obstruction.
- **Salmeterol (Serevent)**: A long-acting bronchodilator that helps keep the airways open [9].

5. **Anti-inflammatory Drugs**

These medications aim to reduce inflammation in the lungs, which can worsen respiratory problems.

- **Ibuprofen**: High-dose ibuprofen can slow the decline in lung function in CF patients by reducing inflammation in the airways.
- **Corticosteroids**: These may be used in certain cases for acute exacerbations or asthma-like symptoms, though long-term use is generally avoided due to side effects [10].

6. **Pancreatic Enzyme Replacements**

Many people with CF have pancreatic insufficiency, meaning their pancreas does not produce enough enzymes to digest food properly.

- **Pancrelipase**: This is a mixture of digestive enzymes (lipase, amylase, and protease) that helps patients absorb nutrients from food [13].

Non-Pharmacological Therapies

Key components of non-pharmacological cystic fibrosis treatment:

- **Airway clearance techniques:**
  - **Chest physiotherapy:** Manual techniques like chest percussion and postural drainage performed by a therapist.
  - **Active cycle breathing (ACBT):** A breathing pattern involving deep breaths, huffing, coughing, and relaxed breathing to mobilize mucus.
  - **Autogenic drainage:** Controlled breathing techniques to clear mucus from the lungs.
  - **Positive expiratory pressure (PEP) devices:** Handheld devices that use air pressure to help clear airways.
  - **High-frequency chest wall oscillation vests:** Wearable devices that vibrate the chest to loosen mucus [10].
- **Nutritional management:**
  - **High-calorie, high-fat diet:** To compensate for malabsorption issues caused by pancreatic insufficiency
  - **Pancreatic enzyme supplements:** To aid digestion by replacing missing pancreatic enzymes
  - **Vitamin supplementation:** Particularly vitamin A, D, E, and K [11].
- **Exercise and pulmonary rehabilitation:**
  - **Regular physical activity:** To improve lung function and overall fitness
  - **Tailored exercise programs:** Designed to manage breathing difficulties and optimize exercise capacity
- **Psychological support:**
  - **Counseling and support groups:** To address the emotional challenges of living with cystic fibrosis.

Lung Transplantation

Lung replacement surgery proves essential as treatment for cystic fibrosis patients because the condition cannot be cured yet while the procedure's performance for this population is clearly established. Multiple advancements in medical science combined with improved treatment approaches and clinical practices for cystic fibrosis (CF) management have occurred throughout several decades. Cytological research into CF organ involvement started with pathology reports in 1938 while ending with DNA sequencing which revealed the CF gene in 1989. The practice of lung transplantation became available for CF patients since 1983 and today cystic fibrosis represents about 17% of all pre-transplantation diagnosis cases [12].

Emerging Therapies for Cystic Fibrosis

The main goal of cystic fibrosis therapy development is the implementation of gene-based approaches for gene editing and gene therapy to correct the disease-causing CFTR gene mutation permanently through procedures such as CRISPR-Cas9 and zinc finger nucleases and RNA therapies that aim to provide a single-time therapeutic solution instead of current symptomatic medication management [12].

Emerging therapies for cystic fibrosis:

- **Gene editing:**

Utilizing technologies like CRISPR-Cas9 to directly modify the CFTR gene within lung cells, potentially correcting the mutation and restoring normal function [14].

- **Gene therapy:**

Delivering a functional CFTR gene into lung cells using viral vectors, aiming to introduce a corrected copy of the gene [14].

- **RNA therapies:**

Using RNA molecules to modulate CFTR expression or correct splicing errors in the CFTR gene [15].

- **Stem cell therapy:**

Harvesting stem cells from a patient, genetically correcting them, and then transplanting them back into the lungs to replenish healthy cells [16].

- **Epithelial sodium channel (ENaC) inhibitors:**

Targeting another protein involved in mucus production in the lungs, potentially offering a treatment option even for patients with mutations not addressed by current CFTR modulators [17].

Challenges in Managing Cystic Fibrosis

Managing cystic fibrosis (CF) can be challenging because of the many complications it can cause, the need for frequent treatments, and the impact on quality of life.

Complications

- **Lung infections**: Thick mucus can trap bacteria in the lungs, making infections difficult to treat
- **Bronchiectasis**: Damaged airways from infections can lead to bronchiectasis, a common complication
- **Cystic fibrosis-related diabetes**: Damage to the pancreas can lead to CFRD
- **Infertility**: Men with CF are infertile
- **Pregnancy complications**: CF can affect the digestive tract, increasing the risk of pregnancy complications.

Treatment challenges

- **Treatment burden**: The need for frequent treatments can lead to non-adherence and low competence with therapy [18].
- **Transition to self-management**: Adolescents and young adults may have difficulty transitioning from parent-directed therapy to self-management [18]
- **Limited evidence base**: There is limited evidence to compare available therapeutic regimens [18].

Quality of Life and Psychological Aspects of Cystic Fibrosis

People who have cystic fibrosis (CF) typically encounter multiple psychological aspects alongside poor quality of life. Depression and anxiety and independence problems along with relationship issues make up the psychological effects of cystic fibrosis [19].

Psychological issues

- **Depression and anxiety**: People with CF have a higher risk of depression and anxiety than the general population.
- **Coping styles**: How people cope with CF can significantly affect their quality of life.
- **Sexuality and relationships**: People with CF may have problems with their sexuality and relationships [20].

Quality of life

- **Physical functioning**: People with CF may score poorly on physical functioning measures of quality of life.
- **Health-related quality of life**: Psychological symptoms are associated with worse health-related quality of life.
- **Hospitalizations**: Psychological symptoms are associated with more frequent hospitalizations.
- **Healthcare costs**: Psychological symptoms are associated with increased healthcare costs [20].

➢ **Current Trends and Future Directions**

Current cystic fibrosis treatment focuses on highly effective CFTR modulators, which have greatly improved lung function and overall health by targeting the genetic defect in the CFTR protein. Future advancements aim to develop therapies for patients with mutations unresponsive to existing modulators, improve management of lung infections, and address the long-term effects of these treatments as the CF population ages. Additionally, ensuring global access to these advanced therapies remains a key priority [21].

➢ **Current trends in cystic fibrosis treatment:**

- **CFTR modulator therapy:**

The greatest progress in CF treatment emerged from developing CFTR modulators which restore functional ability to the defective CFTR protein thus bringing substantial improvements to lung health and total wellness to a significant segment of the CF population [22].

- **Combination therapies:**

Multiple CFTR modulators are now used in combination to maximize efficacy and target a wider range of CFTR mutations.

- **Improved life expectancy:**

Due to the effectiveness of CFTR modulators, the median life expectancy for individuals with CF has significantly increased in recent years [23].

Future directions in cystic fibrosis research:

- **Novel therapies for non-modulator responsive mutations:** Ongoing research explores new treatments, including gene editing techniques like CRISPR-Cas9, for patients with CFTR mutations that do not respond to current modulators.
- **Managing lung infections:** Efforts focus on preventing and treating chronic lung infections, particularly those caused by Pseudomonas aeruginosa, a major complication in CF.
- **Addressing other organ complications:** Research is expanding to treat CF-related conditions beyond lung disease, such as pancreatic insufficiency and liver dysfunction.
- **Early intervention:** Initiating CFTR modulator therapy in young children may enhance long-term outcomes.
- **Personalized medicine:** Genetic profiling is being used to customize treatment plans based on individual CFTR mutations.
- **Long-term impact of CFTR modulators:** Studies are assessing the prolonged effects of these therapies, particularly as the CF population ages [25].

Challenges in future CF care:

- **Access to treatment:**

Ensuring equitable access to expensive CFTR modulators for patients worldwide

- **Clinical trial design:**

Developing appropriate clinical trial designs to evaluate new therapies in a population with significantly improved health due to existing CFTR modulators.

- **Management of complex symptoms:**

Addressing the complex and evolving needs of people with CF who are now living longer lives with the disease.

Conclusion

A person with Cystic Fibrosis has a complex inherited medical condition which damages their lungs as well as their digestive system because CFTR gene mutations prevent salt and water transport so mucus becomes excessively sticky. The development of genetic testing techniques together with CFTR modulator treatments has helped patients by improving their lung function yet the treatment success depends on specific mutation types. The implementation of expensive medical solutions faces difficulties especially in low-resource communities. Predictions for CF treatment involve individualized care methods combined with genetic treatments together with extensive team-based care techniques which boost life quality in patients. Additional improvements in cure development require sustained research in combination with extensive medical care.

References

1. Davis PB. Cystic fibrosis since 1938. American journal of respiratory and critical care medicine. 2006 Mar 1;173(5):475-82.
2. Rafeeq MM, Murad HA. Cystic fibrosis: current therapeutic targets and future approaches. Journal of translational medicine. 2017 Dec;15:1-9.
3. Stern RC. The diagnosis of cystic fibrosis. New England Journal of Medicine. 1997 Feb 13;336(7):487-91.
4. Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical

application. Nature Reviews Genetics. 2015 Jan;16(1):45-56.

5. Yu E, Sankari A, Sharma S. Cystic Fibrosis. [Updated 2024 Dec 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493206/
6. Coderre L, Debieche L, Plourde J, Rabasa-Lhoret R, Lesage S. The potential causes of cystic fibrosis-related diabetes. Frontiers in endocrinology. 2021 Jul 30;12:702823.
7. Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies. Respiratory care. 2009 May 1;54(5):595-605.
8. De Boeck K, Amaral MD. Progress in therapies for cystic fibrosis. The Lancet Respiratory Medicine. 2016 Aug 1;4(8):662-74.
9. Naehrig S, Chao CM, Naehrlich L. Cystic fibrosis: diagnosis and treatment. Deutsches Ärzteblatt International. 2017 Aug 21;114(33-34):564.
10. Guo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. Journal of Cystic Fibrosis. 2022 May 1;21(3):456-62.
11. Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies. Respiratory care. 2009 May 1;54(5):595-605.
12. Huang W, Smith AT, Korotun M, Iacono A, Wang J. Lung transplantation in a new era in the field of cystic fibrosis. Life. 2023 Jul 21;13(7):1600.
13. Graeber SY, Mall MA. The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches. The Lancet. 2023 Sep 30;402(10408):1185-98.
14. Koch C, Høiby N. Diagnosis and treatment of cystic fibrosis. Respiration. 2000 Jan 6;67(3):239-47.
15. Allen L, Allen L, Carr SB, Davies G, Downey D, Egan M, Forton JT, Gray R, Haworth C, Horsley A, Smyth AR, Southern KW, Davies JC. Future therapies for cystic fibrosis. Nat Commun. 2023 Feb 8;14(1):693. doi: 10.1038/s41467-023-36244-2. PMID: 36755044; PMCID: PMC9907205.
16. Pranke I, Golec A, Hinzpeter A, Edelman A, Sermet-Gaudelus I. Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine. Front Pharmacol. 2019 Feb 27;10:121. doi: 10.3389/fphar.2019.00121. PMID: 30873022; PMCID: PMC6400831.
17. Fajac I, De Boeck K. New horizons for cystic fibrosis treatment. Pharmacology & therapeutics. 2017 Feb 1;170:205-11.
18. Davis PB, di Sant'Agnese PA. Diagnosis and treatment of cystic fibrosis: an update. Chest. 1984 Jun 1;85(6):802-9.
19. Jones AM, Helm JM. Emerging treatments in cystic fibrosis. Drugs. 2009 Oct;69:1903-10.
20. Anstey HJ, Caissie DM, Dollimount A, King S, Switzer H, Wright KD. Just Google it: Evaluating Online Mental Health Information for Parents of Children with Cystic Fibrosis. Journal of Child and Family Studies. 2024 Nov;33(11):3602-11.
21. Ernst MM, Johnson MC, Stark LJ. Developmental and psychosocial issues in CF. Child and adolescent psychiatric clinics of North America. 2010 Apr;19(2):263.
22. Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Burgel PR, Tullis E, Castaños C, Castellani C, Byrnes CA. The future of cystic fibrosis care: a global perspective. The Lancet Respiratory Medicine. 2020 Jan 1;8(1):65-124.
23. Edmondson C, Davies JC. Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications. Therapeutic advances in chronic disease. 2016 May;7(3):170-83.
24. Akene E, Song J, Petrovic A. Using Prime Editing and Mesenchymal Stem Cell-Derived Exosomes to Treat Cystic Fibrosis: A Research Protocol. Undergraduate Research in Natural and Clinical Science and Technology Journal. 2022 Feb 4;6:1-8.
25. Ganesh A. Gene Therapy and Gene Editing in Healthcare.